This 2019 review explores drug repurposing as a cost-effective and time-saving strategy in oncology, highlighting its potential to expedite the development of cancer treatments. The authors discuss several non-oncologic drugs—such as artesunate, aspirin, cimetidine, doxycycline, ivermectin, metformin, rapamycin, and thalidomide—that exhibit anticancer properties through mechanisms like apoptosis induction, angiogenesis inhibition,
